Claire S. Whyte
The suboptimal fibrinolytic response in COVID-19 is dictated by high PAI-1.
Whyte, Claire S.; Simpson, Megan; Morrow, Gael B.; Wallace, Carol A.; Mentzer, Alexander J.; Knight, Julian C.; Shapiro, Susan; Curry, Nicola; Bagot, Catherine N.; Watson, Henry; Cooper, Jamie G.; Mutch, Nicola J.
Authors
Megan Simpson
Dr Gael Morrow g.morrow1@rgu.ac.uk
Chancellor's Fellow
Carol A. Wallace
Alexander J. Mentzer
Julian C. Knight
Susan Shapiro
Nicola Curry
Catherine N. Bagot
Henry Watson
Jamie G. Cooper
Nicola J. Mutch
Abstract
Severe COVID-19 disease is associated with thrombotic complications and extensive fibrin deposition. This study investigates whether the hemostatic complications in COVID-19 disease arise due to dysregulation of the fibrinolytic system. This prospective study analyzed fibrinolytic profiles of 113 patients hospitalized with COVID-19 disease with 24 patients with non-COVID-19 respiratory infection and healthy controls. Antigens were quantified by Ella system or ELISA, clot lysis by turbidimetric assay, and plasminogen activator inhibitor-1 (PAI-1)/plasmin activity using chromogenic substrates. Clot structure was visualized by confocal microscopy. PAI-1 and its cofactor, vitronectin, are significantly elevated in patients with COVID-19 disease compared with those with non-COVID-19 respiratory infection and healthy control groups. Thrombin activatable fibrinolysis inhibitor and tissue plasminogen activator were elevated in patients with COVID-19 disease relative to healthy controls. PAI-1 and tissue plasminogen activator (tPA) were associated with more severe COVID-19 disease severity. Clots formed from COVID-19 plasma demonstrate an altered fibrin network, with attenuated fiber length and increased branching. Functional studies reveal that plasmin generation and clot lysis were markedly attenuated in COVID-19 disease, while PAI-1 activity was elevated. Clot lysis time significantly correlated with PAI-1 levels. Stratification of COVID-19 samples according to PAI-1 levels reveals significantly faster lysis when using the PAI-1 resistant (tPA) variant, tenecteplase, over alteplase lysis. This study shows that the suboptimal fibrinolytic response in COVID-19 disease is directly attributable to elevated levels of PAI-1, which attenuate plasmin generation. These data highlight the important prognostic potential of PAI-1 and the possibility of using pre-existing drugs, such as tenecteplase, to treat COVID-19 disease and potentially other respiratory diseases.
Citation
WHYTE, C.S., SIMPSON, M., MORROW, G.B., WALLACE, C.A., MENTZER, A.J., KNIGHT, J.C., SHAPIRO, S., CURRY, N., BAGOT, C.N., WATSON, H., COOPER, J.G. and MUTCH, N.J. 2022. The suboptimal fibrinolytic response in COVID-19 is dictated by high PAI-1. Journal of thrombosis and haemostasis [online], 20(10), pages 2394-2406. Available from: https://doi.org/10.1111/jth.15806
Journal Article Type | Article |
---|---|
Acceptance Date | Aug 30, 2022 |
Online Publication Date | Sep 19, 2023 |
Publication Date | Oct 31, 2022 |
Deposit Date | Jul 25, 2023 |
Publicly Available Date | Jul 25, 2023 |
Journal | Journal of thrombosis and haemostasis |
Print ISSN | 1538-7933 |
Electronic ISSN | 1538-7836 |
Publisher | Wiley |
Peer Reviewed | Peer Reviewed |
Volume | 20 |
Issue | 10 |
Pages | 2394-2406 |
DOI | https://doi.org/10.1111/jth.15806 |
Keywords | COVID-19; Fibrin; Fibrinolysis; PAI-1; Vitronectin |
Public URL | https://rgu-repository.worktribe.com/output/2010403 |
Additional Information | This article has been published with separate supporting information. This supporting information has been incorporated into a single file on this repository and can be found at the end of the file associated with this output. |
Files
WHYTE 2022 The suboptimal fibrinolytic (VOR)
(5.4 Mb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by/4.0/
Copyright Statement
© 2022 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis.
You might also like
Past, present, and future perspectives of plasminogen activator inhibitor 1 (PAI-1).
(2022)
Journal Article
Downloadable Citations
About OpenAIR@RGU
Administrator e-mail: publications@rgu.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search